A

Active Director Director DIN 10846890
DIN 10846890 First appointment Nov 2024 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 2 active board seats
Total affiliations 2 Since Nov 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Ashker

Data last updated:

Ashker is a Director at Gradiks Global Studies Private Limited (since 2026) and Director at Carnelian Pharmaceuticals Private Limited (since 2024). The companies operate in Pharma.

DIN 10846890
Primary Designation Director
Industry Pharma
First Appointment 22 Nov 2024
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director26 Feb 20262026Active
Director22 Nov 20242024Active

Board colleagues of Ashker

Directorship timeline

Open interactive timeline →
Carnelian Pharmaceuticals Private Limited
Gradiks Global Studies Private Limited
Premium access

Shareholding and investment profile for Ashker

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ashker

Ashker currently holds 2 directorships: Gradiks Global Studies Private Limited (Director, since 26 Feb 2026); Carnelian Pharmaceuticals Private Limited (Director, since 22 Nov 2024).

Ashker was first appointed on 22 Nov 2024 as Director at Carnelian Pharmaceuticals Private Limited. The most recent appointment on record is 26 Feb 2026 at Gradiks Global Studies Private Limited.

The current boards of Ashker's companies include Nuhaz Mundamgulam (Gradiks Global Studies Private Limited), Mohamedali Jawhar (Carnelian Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available